BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-112@pharmaconomics
DTSTAMP:20260707T034233Z
DTSTART;VALUE=DATE:20261229
DTEND;VALUE=DATE:20261230
SUMMARY:GENE Phase 2 — Alirocumab
DESCRIPTION:Phase 2 trial results for Alirocumab in Hypercholesterolemia are due Dec 29\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT07477704\n\nTrack it: https://www.pharmaconomics.com/e/112
URL:https://www.pharmaconomics.com/e/112
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:GENE catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR